Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase 1/2 Dose-Finding Study to Evaluate the Safety, Feasibility, and Activity of BPX-701, a Controllable PRAME T-Cell Receptor Therapy, in HLA-A2+ Subjects With AML, Previously Treated MDS, or Metastatic Uveal Melanoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02743611
• Other study ID #: BP-011
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: April 14, 2017
• Est. completion date: July 19, 2020

Study information

• Verified date: June 2023
• Source: Bellicum Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.

Description:

The goal of this study is to characterize the safety, feasibility, and clinical activity of BPX-701, a genetically modified autologous T cell product incorporating an HLA-A2-restricted PRAME-directed TCR and a rimiducid-inducible safety switch, when administered to subjects with relapsed AML, previously treated MDS, or metastatic uveal melanoma.

The study will be comprised of multiple parts:

Part 1 (Phase 1): Cell dose escalation to identify the maximum dose of BPX-701 T cells (escalating doses from 1.25 x 10E6 cells/kg up to 5.0 x 10E6 cells/kg to be explored) Parts 2 and 3 (Phase 2): Dose expansion to assess the safety, pharmacodynamics (including BPX-701 T cell persistence and response to rimiducid as applicable), and clinical activity at the recommended dose identified in Part 1 During Parts 1, 2, or 3, rimiducid may be administered following BPX-701 T cell infusion in response to uncontrollable, treatment-emergent toxicity

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: July 19, 2020
• Est. primary completion date: July 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Signed informed consent

2. Participants in Arm 1:

MDS not responding to hypomethylation therapy or recurrence after initial response AML with disease relapse following first complete remission with intermediate or adverse genetics according to the European Leukemia Net criteria. AML participants with prior stem cell transplant must be >100 days post-transplant with no evidence of active graft-versus-host disease and not requiring systemic immunomodulatory or immunosuppressive therapy (>10mg prednisone daily or treatment with a calcineurin inhibitor)

3. Participants in Arm 2:

Metastatic uveal melanoma with a radiographically measurable tumor, absolute neutrophil count >/=1000/uL, and platelets >/=75,000/uL

4. HLA-A2.01 positive by local testing

5. Tumor with positive PRAME expression by central testing

6. Age >/= 18 years

7. Participant has a life expectancy >12 weeks and is able to carry out daily life activities without difficulty (Eastern Cooperative Oncology Group performance status 0 or 1).

8. Participant has adequate venous access for apheresis or agrees to use of a central line for blood collection.

9. Participant does not have significant side effects from previous anticancer treatment.

10. Adequate organ function including absolute lymphocyte count >/=200/uL.

11. Sexually active participants must use medically acceptable methods of contraception for at least 1 year after study treatment.

Exclusion Criteria

1. Participants with AML must not have:

• Acute promyelocytic leukemia,

• Primary refractory disease,

• Uncontrolled disseminated intravascular coagulation,

• Signs or symptoms of cancer cells in the brain or nervous system,

• Peripheral blast count >/=20,000/uL

2. Participants with uveal melanoma must not have an untreated brain tumor

3. Participant has a history of major surgery or treatment with other cancer therapy within 2-4 weeks (1 week for hydroxyurea) before study treatment.

4. Participant has an active, autoimmune disease that requires immunosuppressive therapy. Exceptions are vitiligo, type I diabetes, certain cases of hypothyroidism and psoriasis, or Hashimoto's thyroiditis on a stable dose of thyroid replacement therapy

5. History of clinically significant heart problems.

6. Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics within 2 weeks before study treatment.

7. Participant is currently pregnant or breastfeeding.

8. Participant requires chronic, systemic steroid therapy.

9. Participant is positive for Hepatitis B, Hepatitis C, HIV, syphilis, West Nile virus, or Chagas disease.

10. Participant has side effects from earlier cancer treatment that have not resolved

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Melanoma
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Uveal Melanoma
• Uveal Neoplasms

Intervention

Biological:
• BPX-701
autologous T cells genetically modified to express the aß TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Drug:
• Rimiducid
dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Locations

Country	Name	City	State
United States	Colorado Blood Cancer Institute	Denver	Colorado
United States	Tennessee Oncology	Nashville	Tennessee
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Bellicum Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1 Arm 1: Dose-limiting Toxicity	Incidence of dose limiting-toxicity (DLT)	28 days after BPX-701 infusion
Primary	Part 1 Arm 1: Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)	Number of participants with AEs and SAEs assessed for severity using CTCAE	15 months